Subscribe
roads_istock-577629414_sonercdem
sonercdem / iStockphoto.com
22 June 2017Americas

BIO 2017: Industry at a crossroads over section 101

The biotechnology industry is at a crossroads over 35 USC section 101, which covers patent subject matter eligibility.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
BIO 2018: Stop bashing the patent system, says USPTO director
5 June 2018   “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
BIO 2018: Stop bashing the patent system, says USPTO director
5 June 2018   “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”

More on this story

Americas
BIO 2018: Stop bashing the patent system, says USPTO director
5 June 2018   “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”

More features

Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic